ID   SIAH2_HUMAN             Reviewed;         324 AA.
AC   O43255; O43270;
DT   26-APR-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   10-MAY-2017, entry version 156.
DE   RecName: Full=E3 ubiquitin-protein ligase SIAH2;
DE            EC=2.3.2.27;
DE   AltName: Full=RING-type E3 ubiquitin transferase SIAH2 {ECO:0000305};
DE   AltName: Full=Seven in absentia homolog 2;
DE            Short=Siah-2;
DE            Short=hSiah2;
GN   Name=SIAH2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=9403064; DOI=10.1006/geno.1997.4997;
RA   Hu G., Chung Y.-L., Glover T., Valentine V., Look A.T., Fearon E.R.;
RT   "Characterization of human homologs of the Drosophila seven in
RT   absentia (sina) gene.";
RL   Genomics 46:103-111(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INTERACTION WITH VAV1.
RX   PubMed=10207103; DOI=10.1128/MCB.19.5.3798;
RA   Germani A., Romero F., Houlard M., Camonis J., Gisselbrecht S.,
RA   Fischer S., Varin-Blank N.;
RT   "hSiah2 is a new Vav binding protein which inhibits Vav-mediated
RT   signaling pathways.";
RL   Mol. Cell. Biol. 19:3798-3807(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION IN DEGRADATION OF DCC, AND INTERACTION WITH UBE2I.
RX   PubMed=9334332; DOI=10.1101/gad.11.20.2701;
RA   Hu G., Zhang S., Vidal M., Baer J.L., Xu T., Fearon E.R.;
RT   "Mammalian homologs of seven in absentia regulate DCC via the
RT   ubiquitin-proteasome pathway.";
RL   Genes Dev. 11:2701-2714(1997).
RN   [5]
RP   FUNCTION IN DEGRADATION OF POU2AF1.
RX   PubMed=11483518; DOI=10.1093/emboj/20.15.4153;
RA   Boehm J., He Y., Greiner A., Staudt L., Wirth T.;
RT   "Regulation of BOB.1/OBF.1 stability by SIAH.";
RL   EMBO J. 20:4153-4162(2001).
RN   [6]
RP   INTERACTION WITH CACYBP.
RX   PubMed=11389839; DOI=10.1016/S1097-2765(01)00242-8;
RA   Matsuzawa S., Reed J.C.;
RT   "Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin
RT   degradation linked to p53 responses.";
RL   Mol. Cell 7:915-926(2001).
RN   [7]
RP   FUNCTION IN DEGRADATION OF TRAF2.
RX   PubMed=12411493; DOI=10.1093/emboj/cdf576;
RA   Habelhah H., Frew I.J., Laine A., Janes P.W., Relaix F., Sassoon D.,
RA   Bowtell D.D.L., Ronai Z.;
RT   "Stress-induced decrease in TRAF2 stability is mediated by Siah2.";
RL   EMBO J. 21:5756-5765(2002).
RN   [8]
RP   INTERACTION WITH PEG10.
RX   PubMed=12810624;
RA   Okabe H., Satoh S., Furukawa Y., Kato T., Hasegawa S., Nakajima Y.,
RA   Yamaoka Y., Nakamura Y.;
RT   "Involvement of PEG10 in human hepatocellular carcinogenesis through
RT   interaction with SIAH1.";
RL   Cancer Res. 63:3043-3048(2003).
RN   [9]
RP   INTERACTION WITH EGLN2.
RX   PubMed=16509823; DOI=10.1042/BJ20051996;
RA   Tian Y.M., Mole D.R., Ratcliffe P.J., Gleadle J.M.;
RT   "Characterization of different isoforms of the HIF prolyl hydroxylase
RT   PHD1 generated by alternative initiation.";
RL   Biochem. J. 397:179-186(2006).
RN   [10]
RP   FUNCTION, INTERACTION WITH SNCAIP, SUBCELLULAR LOCATION, AND ENZYME
RP   REGULATION.
RX   PubMed=19224863; DOI=10.1074/jbc.M805990200;
RA   Szargel R., Rott R., Eyal A., Haskin J., Shani V., Balan L.,
RA   Wolosker H., Engelender S.;
RT   "Synphilin-1A inhibits seven in absentia homolog (SIAH) and modulates
RT   alpha-synuclein monoubiquitylation and inclusion formation.";
RL   J. Biol. Chem. 284:11706-11716(2009).
RN   [11]
RP   FUNCTION, INTERACTION WITH DYRK2, SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION AT SER-16; THR-26; SER-28; SER-68 AND THR-119,
RP   MUTAGENESIS OF SER-16; THR-26; SER-28; SER-68 AND THR-119, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22878263; DOI=10.1093/jmcb/mjs047;
RA   Perez M., Garcia-Limones C., Zapico I., Marina A., Schmitz M.L.,
RA   Munoz E., Calzado M.A.;
RT   "Mutual regulation between SIAH2 and DYRK2 controls hypoxic and
RT   genotoxic signaling pathways.";
RL   J. Mol. Cell Biol. 4:316-330(2012).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that mediates ubiquitination
CC       and subsequent proteasomal degradation of target proteins. E3
CC       ubiquitin ligases accept ubiquitin from an E2 ubiquitin-
CC       conjugating enzyme in the form of a thioester and then directly
CC       transfers the ubiquitin to targeted substrates. Mediates E3
CC       ubiquitin ligase activity either through direct binding to
CC       substrates or by functioning as the essential RING domain subunit
CC       of larger E3 complexes. Triggers the ubiquitin-mediated
CC       degradation of many substrates, including proteins involved in
CC       transcription regulation (POU2AF1, PML, NCOR1), a cell surface
CC       receptor (DCC), an antiapoptotic protein (BAG1), and a protein
CC       involved in synaptic vesicle function in neurons (SYP). Mediates
CC       ubiquitination and proteasomal degradation of DYRK2 in response to
CC       hypoxia. It is thereby involved in apoptosis, tumor suppression,
CC       cell cycle, transcription and signaling processes. Has some
CC       overlapping function with SIAH1. Triggers the ubiquitin-mediated
CC       degradation of TRAF2, whereas SIAH1 does not. Promotes
CC       monoubiquitination of SNCA. {ECO:0000269|PubMed:11483518,
CC       ECO:0000269|PubMed:12411493, ECO:0000269|PubMed:19224863,
CC       ECO:0000269|PubMed:22878263, ECO:0000269|PubMed:9334332}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- ENZYME REGULATION: Inhibited by interaction with SNCAIP (isoform
CC       2, but not isoform 1). May be inhibited by interaction with PEG10.
CC       {ECO:0000269|PubMed:19224863}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Homodimer. Interacts with UBE2E2. Interacts with PEG3 (By
CC       similarity). Interacts with VAV1, without mediating its ubiquitin-
CC       mediated degradation. Interacts with CACYBP/SIP. Probable
CC       component of some large E3 complex possibly composed of UBE2D1,
CC       SIAH2, CACYBP/SIP, SKP1, APC and TBL1X. Interacts with PEG10,
CC       which may inhibit its activity. Interacts with EGLN2 and SNCAIP.
CC       Interacts with DYRK2. {ECO:0000250, ECO:0000269|PubMed:10207103,
CC       ECO:0000269|PubMed:11389839, ECO:0000269|PubMed:12810624,
CC       ECO:0000269|PubMed:16509823, ECO:0000269|PubMed:19224863,
CC       ECO:0000269|PubMed:22878263, ECO:0000269|PubMed:9334332}.
CC   -!- INTERACTION:
CC       P35372:OPRM1; NbExp=3; IntAct=EBI-948141, EBI-2624570;
CC       Q7Z6J0:SH3RF1; NbExp=2; IntAct=EBI-948141, EBI-311339;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Predominantly
CC       cytoplasmic. Partially nuclear.
CC   -!- TISSUE SPECIFICITY: Widely expressed at low level.
CC       {ECO:0000269|PubMed:9403064}.
CC   -!- DOMAIN: The RING-type zinc finger domain is essential for
CC       ubiquitin ligase activity.
CC   -!- DOMAIN: The SBD domain (substrate-binding domain) mediates the
CC       homodimerization and the interaction with substrate proteins. It
CC       is related to the TRAF family. {ECO:0000250}.
CC   -!- PTM: Phosphorylated at Ser-28 by MAPK14, which mediates the
CC       degradation by the proteasome of EGLN3 (By similarity).
CC       Phosphorylated at Ser-28 by DYRK2; this increases the ubiquitin
CC       ligase activity and promotes degradation of EGLN3. {ECO:0000250,
CC       ECO:0000269|PubMed:22878263}.
CC   -!- SIMILARITY: Belongs to the SINA (Seven in absentia) family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/SIAH2ID46199ch3q25.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U76248; AAC51908.1; -; mRNA.
DR   EMBL; Y15268; CAA75557.1; -; mRNA.
DR   EMBL; BC013082; AAH13082.1; -; mRNA.
DR   CCDS; CCDS3152.1; -.
DR   RefSeq; NP_005058.3; NM_005067.5.
DR   UniGene; Hs.477959; -.
DR   UniGene; Hs.692394; -.
DR   PDB; 5H9M; X-ray; 1.76 A; A/B=131-321.
DR   PDBsum; 5H9M; -.
DR   ProteinModelPortal; O43255; -.
DR   SMR; O43255; -.
DR   BioGrid; 112373; 70.
DR   DIP; DIP-41874N; -.
DR   IntAct; O43255; 16.
DR   MINT; MINT-200601; -.
DR   STRING; 9606.ENSP00000322457; -.
DR   iPTMnet; O43255; -.
DR   PhosphoSitePlus; O43255; -.
DR   BioMuta; SIAH2; -.
DR   MaxQB; O43255; -.
DR   PaxDb; O43255; -.
DR   PeptideAtlas; O43255; -.
DR   PRIDE; O43255; -.
DR   Ensembl; ENST00000312960; ENSP00000322457; ENSG00000181788.
DR   GeneID; 6478; -.
DR   KEGG; hsa:6478; -.
DR   UCSC; uc003eyi.4; human.
DR   CTD; 6478; -.
DR   DisGeNET; 6478; -.
DR   GeneCards; SIAH2; -.
DR   H-InvDB; HIX0163461; -.
DR   HGNC; HGNC:10858; SIAH2.
DR   HPA; CAB069930; -.
DR   HPA; HPA061293; -.
DR   MIM; 602213; gene.
DR   neXtProt; NX_O43255; -.
DR   OpenTargets; ENSG00000181788; -.
DR   PharmGKB; PA35760; -.
DR   eggNOG; KOG3002; Eukaryota.
DR   eggNOG; ENOG410XVP0; LUCA.
DR   GeneTree; ENSGT00390000005434; -.
DR   HOGENOM; HOG000231487; -.
DR   HOVERGEN; HBG055701; -.
DR   InParanoid; O43255; -.
DR   KO; K08742; -.
DR   OMA; KQCRQKL; -.
DR   OrthoDB; EOG091G0BPY; -.
DR   PhylomeDB; O43255; -.
DR   TreeFam; TF312976; -.
DR   Reactome; R-HSA-373752; Netrin-1 signaling.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SIGNOR; O43255; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; SIAH2; human.
DR   GeneWiki; SIAH2; -.
DR   GenomeRNAi; 6478; -.
DR   PRO; PR:O43255; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000181788; -.
DR   CleanEx; HS_SIAH2; -.
DR   ExpressionAtlas; O43255; baseline and differential.
DR   Genevisible; O43255; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005769; C:early endosome; IEA:Ensembl.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003714; F:transcription corepressor activity; TAS:ProtInc.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IEA:Ensembl.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; EXP:Reactome.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0044257; P:cellular protein catabolic process; IGI:MGI.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IGI:MGI.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0000209; P:protein polyubiquitination; TAS:Reactome.
DR   GO; GO:0031396; P:regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:ProtInc.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; TAS:ProtInc.
DR   Gene3D; 2.60.210.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR018121; 7-in-absentia-prot_TRAF-dom.
DR   InterPro; IPR004162; SINA-like.
DR   InterPro; IPR008974; TRAF-like.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR013010; Znf_SIAH.
DR   PANTHER; PTHR10315; PTHR10315; 1.
DR   Pfam; PF03145; Sina; 1.
DR   SUPFAM; SSF49599; SSF49599; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
DR   PROSITE; PS51081; ZF_SIAH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; Cell cycle; Complete proteome; Cytoplasm;
KW   Metal-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Transferase; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    324       E3 ubiquitin-protein ligase SIAH2.
FT                                /FTId=PRO_0000056168.
FT   ZN_FING      80    115       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   ZN_FING     133    193       SIAH-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00455}.
FT   REGION      130    322       SBD.
FT   METAL       138    138       Zinc 1. {ECO:0000250}.
FT   METAL       145    145       Zinc 1. {ECO:0000250}.
FT   METAL       157    157       Zinc 1. {ECO:0000250}.
FT   METAL       161    161       Zinc 1. {ECO:0000250}.
FT   METAL       168    168       Zinc 2. {ECO:0000250}.
FT   METAL       175    175       Zinc 2. {ECO:0000250}.
FT   METAL       187    187       Zinc 2. {ECO:0000250}.
FT   METAL       192    192       Zinc 2. {ECO:0000250}.
FT   MOD_RES       6      6       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      16     16       Phosphoserine; by DYRK2.
FT                                {ECO:0000269|PubMed:22878263}.
FT   MOD_RES      26     26       Phosphothreonine; by DYRK2.
FT                                {ECO:0000269|PubMed:22878263}.
FT   MOD_RES      28     28       Phosphoserine; by DYRK2 and MAPK14.
FT                                {ECO:0000269|PubMed:22878263}.
FT   MOD_RES      68     68       Phosphoserine; by DYRK2.
FT                                {ECO:0000269|PubMed:22878263}.
FT   MOD_RES     119    119       Phosphothreonine; by DYRK2.
FT                                {ECO:0000269|PubMed:22878263}.
FT   MUTAGEN      16     16       S->A: Strongly reduced phosphorylation by
FT                                DYRK2; when associated with A-26; A-28;
FT                                A-68 and A-119.
FT                                {ECO:0000269|PubMed:22878263}.
FT   MUTAGEN      26     26       T->A: Strongly reduced phosphorylation by
FT                                DYRK2; when associated with A-16; A-28;
FT                                A-68 and A-119.
FT                                {ECO:0000269|PubMed:22878263}.
FT   MUTAGEN      28     28       S->A: Strongly reduced phosphorylation by
FT                                DYRK2; when associated with A-16; A-26;
FT                                A-68 and A-119.
FT                                {ECO:0000269|PubMed:22878263}.
FT   MUTAGEN      68     68       S->A: Strongly reduced phosphorylation by
FT                                DYRK2; when associated with A-16; A-26;
FT                                A-28 and A-119.
FT                                {ECO:0000269|PubMed:22878263}.
FT   MUTAGEN     119    119       T->A: Strongly reduced phosphorylation by
FT                                DYRK2; when associated with A-16; A-26;
FT                                A-28 and A-68.
FT                                {ECO:0000269|PubMed:22878263}.
FT   CONFLICT    200    200       G -> E (in Ref. 1; AAC51908).
FT                                {ECO:0000305}.
FT   STRAND      135    137       {ECO:0000244|PDB:5H9M}.
FT   HELIX       141    143       {ECO:0000244|PDB:5H9M}.
FT   STRAND      148    150       {ECO:0000244|PDB:5H9M}.
FT   TURN        151    153       {ECO:0000244|PDB:5H9M}.
FT   HELIX       154    160       {ECO:0000244|PDB:5H9M}.
FT   HELIX       181    183       {ECO:0000244|PDB:5H9M}.
FT   HELIX       184    191       {ECO:0000244|PDB:5H9M}.
FT   STRAND      196    207       {ECO:0000244|PDB:5H9M}.
FT   STRAND      217    224       {ECO:0000244|PDB:5H9M}.
FT   STRAND      227    239       {ECO:0000244|PDB:5H9M}.
FT   STRAND      242    253       {ECO:0000244|PDB:5H9M}.
FT   HELIX       255    258       {ECO:0000244|PDB:5H9M}.
FT   STRAND      262    269       {ECO:0000244|PDB:5H9M}.
FT   STRAND      272    278       {ECO:0000244|PDB:5H9M}.
FT   HELIX       283    285       {ECO:0000244|PDB:5H9M}.
FT   HELIX       288    292       {ECO:0000244|PDB:5H9M}.
FT   STRAND      296    300       {ECO:0000244|PDB:5H9M}.
FT   HELIX       301    307       {ECO:0000244|PDB:5H9M}.
FT   STRAND      312    320       {ECO:0000244|PDB:5H9M}.
SQ   SEQUENCE   324 AA;  34615 MW;  2D5DD845666EC924 CRC64;
     MSRPSSTGPS ANKPCSKQPP PQPQHTPSPA APPAAATISA AGPGSSAVPA AAAVISGPGG
     GGGAGPVSPQ HHELTSLFEC PVCFDYVLPP ILQCQAGHLV CNQCRQKLSC CPTCRGALTP
     SIRNLAMEKV ASAVLFPCKY ATTGCSLTLH HTEKPEHEDI CEYRPYSCPC PGASCKWQGS
     LEAVMSHLMH AHKSITTLQG EDIVFLATDI NLPGAVDWVM MQSCFGHHFM LVLEKQEKYE
     GHQQFFAIVL LIGTRKQAEN FAYRLELNGN RRRLTWEATP RSIHDGVAAA IMNSDCLVFD
     TAIAHLFADN GNLGINVTIS TCCP
//
